Windtree Amends S-1 for Continuous Offering, Signaling Funding Needs
Ticker: WINTW · Form: S-1/A · Filed: Jul 7, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | S-1/A |
| Filed Date | Jul 7, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biotechnology, S-1/A Filing, Continuous Offering, Dilution Risk, SEC Filing, Capital Raise, Pharmaceuticals
Related Tickers: WINTW
TL;DR
**WINTW's continuous offering is a red flag for dilution, signaling ongoing capital needs for this biotech.**
AI Summary
WINDTREE THERAPEUTICS INC /DE/ (WINTW) filed an S-1/A on July 7, 2025, for a delayed or continuous offering of securities under Rule 415. The company, a biological products firm (SIC 2836), is headquartered at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania. This amendment updates their initial S-1 filing, Registration No. 333-287358, indicating ongoing capital raising efforts. While specific revenue and net income figures are not detailed in this excerpt, the continuous offering suggests a need for sustained funding for its operations and product development. Key business changes include the company's historical name changes from ANSAN INC to DISCOVERY LABORATORIES INC /DE/ before becoming WINDTREE THERAPEUTICS INC /DE/. The primary risk highlighted is the inherent uncertainty of a continuous offering, which can dilute existing shareholder value over time. The strategic outlook is focused on leveraging this offering to support its biological product pipeline, with Jed Latkin serving as President and CEO.
Why It Matters
This S-1/A filing signals WINDTREE THERAPEUTICS' intent to raise capital on an ongoing basis, which could lead to significant dilution for existing WINTW shareholders if new shares are issued at lower prices. For employees, it suggests continued investment in the company's pipeline, potentially securing jobs but also indicating a reliance on external funding. Customers might see this as a positive sign of sustained product development, while the broader market will watch how this impacts WINTW's competitive position against larger, more financially stable biotech firms. The continuous offering mechanism provides flexibility but also introduces uncertainty regarding the timing and pricing of future share issuances.
Risk Assessment
Risk Level: high — The risk level is high due to the nature of a continuous offering under Rule 415, which allows for ongoing dilution of existing shareholder value without immediate transparency on pricing or timing. As a biological products company (SIC 2836), WINDTREE THERAPEUTICS faces inherent R&D risks and a long path to commercialization, making sustained capital crucial but also potentially costly for investors. The lack of specific financial performance data in this excerpt further elevates the risk.
Analyst Insight
Investors should exercise extreme caution and thoroughly research WINDTREE THERAPEUTICS' financial statements and product pipeline before considering investment. Monitor the volume and pricing of any shares issued under this continuous offering, as significant dilution could negatively impact share price. Consider the company's burn rate and cash position.
Key Numbers
- 2025-07-07 — Filing Date (Date the S-1/A was filed with the SEC)
- 333-287358 — Registration No. (The specific registration number for this S-1 filing)
- 2836 — SIC Code (Primary Standard Industrial Classification Code for Biological Products)
- 215-488-9300 — Business Phone (Contact number for Windtree Therapeutics, Inc.)
- Rule 415 — SEC Rule (Indicates a delayed or continuous offering of securities)
Key Players & Entities
- WINDTREE THERAPEUTICS INC /DE/ (company) — Registrant and biological products firm
- Jed Latkin (person) — President and Chief Executive Officer of Windtree Therapeutics, Inc.
- Faith L. Charles, Esq. (person) — Attorney at Thompson Hine LLP
- Thompson Hine LLP (company) — Legal counsel for the registrant
- SEC (regulator) — Securities and Exchange Commission
- Rule 415 (regulator) — SEC rule governing delayed or continuous offerings
- 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (company) — Principal executive offices of Windtree Therapeutics, Inc.
- 0000946486 (company) — Central Index Key (CIK) for Windtree Therapeutics Inc /DE/
- 333-287358 (regulator) — Registration Statement number for the S-1 filing
- 94-3171943 (company) — I.R.S. Employer Identification No. for Windtree Therapeutics, Inc.
FAQ
What is the purpose of Windtree Therapeutics' S-1/A filing?
The S-1/A filing by Windtree Therapeutics is an amendment to their initial S-1 registration statement, specifically indicating a delayed or continuous offering of securities pursuant to Rule 415 under the Securities Act of 1933. This allows the company to raise capital over time as needed.
Who is the CEO of Windtree Therapeutics?
Jed Latkin is the President and Chief Executive Officer of Windtree Therapeutics, Inc. His contact information is listed as 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976, with a phone number of (215) 488-9300.
What industry does Windtree Therapeutics operate in?
Windtree Therapeutics operates in the biological products industry, as indicated by its Primary Standard Industrial Classification Code Number 2836. This sector typically involves research, development, and manufacturing of biological substances.
What are the potential risks for investors with Windtree Therapeutics' continuous offering?
A continuous offering under Rule 415 carries a significant risk of dilution for existing shareholders. As new shares are issued over time, the ownership percentage of current investors may decrease, potentially impacting the per-share value of their holdings.
Where are Windtree Therapeutics' principal executive offices located?
Windtree Therapeutics' principal executive offices are located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976. Their business phone number is (215) 488-9300.
What was Windtree Therapeutics' former company name?
Windtree Therapeutics Inc /DE/ was formerly known as DISCOVERY LABORATORIES INC /DE/, with a name change date of 19971201. Prior to that, it was ANSAN PHARMACEUTICALS INC and ANSAN INC.
What is the significance of the 'As soon as practicable' statement in the S-1/A filing?
The statement 'As soon as practicable after the effective date of this Registration Statement' indicates that Windtree Therapeutics intends to commence the sale of securities under the continuous offering as soon as regulatory requirements are met, providing flexibility in timing for capital raises.
What is the SEC file number for Windtree Therapeutics' S-1/A?
The SEC file number for Windtree Therapeutics' S-1/A filing is 333-287358. This number identifies the specific registration statement with the Securities and Exchange Commission.
How does a continuous offering impact Windtree Therapeutics' financial strategy?
A continuous offering provides Windtree Therapeutics with a flexible mechanism to raise capital as needed, which is crucial for a biotechnology company with ongoing research and development expenses. It allows them to tap into the market opportunistically without filing a new registration statement for each offering.
Who is the agent for service for Windtree Therapeutics?
Jed Latkin, President and Chief Executive Officer of Windtree Therapeutics, Inc., is also listed as the agent for service. His address is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976, and his phone number is (215) 488-9300.
Risk Factors
- Continuous Offering Dilution [medium — financial]: The company is utilizing Rule 415 for a delayed or continuous offering of securities. This method allows for ongoing capital raising, which inherently carries the risk of diluting the ownership stake of existing shareholders over time as new shares are issued.
Industry Context
Windtree Therapeutics operates within the biological products sector (SIC 2836), a highly competitive and innovation-driven industry. Companies in this space focus on developing novel therapeutics, often requiring substantial R&D investment and facing lengthy regulatory approval processes. The industry is characterized by significant scientific advancements, patent protection, and the potential for high rewards but also substantial risks.
Regulatory Implications
As a biological products firm, Windtree Therapeutics is subject to stringent regulatory oversight by bodies like the FDA. The S-1/A filing itself is a regulatory requirement for public offerings. The continuous offering mechanism under Rule 415 also has regulatory implications regarding disclosure and ongoing compliance.
What Investors Should Do
- Monitor continuous offering activity
- Evaluate pipeline progress
Key Dates
- 2025-07-07: Filing of S-1/A Amendment — Indicates the company is actively seeking to raise capital through a continuous offering, updating its previous registration statement.
- 1997-12-01: Name Change to Discovery Laboratories Inc /DE/ — Part of the company's historical evolution, reflecting potential shifts in strategy or focus prior to its current identity.
- 1996-11-21: Name Change to Ansan Pharmaceuticals Inc — Another historical name change, illustrating the company's corporate lineage.
- 1995-06-09: Name Change from Ansan Inc — Marks the earliest recorded name change in the company's history provided.
Glossary
- Rule 415
- A U.S. Securities and Exchange Commission (SEC) rule that permits companies to register securities for delayed or continuous offerings over a period of time. (This filing indicates the company is using Rule 415, meaning it plans to sell securities incrementally, which can impact stock price and shareholder value over time due to potential dilution.)
- S-1/A
- An amendment to an S-1 registration statement filed with the SEC. The S-1 is the initial filing required for companies going public or offering new securities. (This amendment updates the company's registration for an ongoing securities offering, signaling continued capital-raising activities.)
- SIC Code 2836
- Standard Industrial Classification code for 'Biological Products (no diagnostic substances)'. (This code categorizes Windtree Therapeutics as a company primarily involved in the development and manufacturing of biological products, placing it within a specific sector of the pharmaceutical and biotechnology industry.)
Year-Over-Year Comparison
This filing is an amendment (S-1/A) to a previous registration statement (Registration No. 333-287358). As an amendment, it updates information rather than presenting a year-over-year comparison of financial metrics. The primary focus is on enabling a continuous offering under Rule 415, indicating a strategy for ongoing capital infusion rather than a review of past performance against a prior period.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on July 7, 2025 by Jed Latkin regarding WINDTREE THERAPEUTICS INC /DE/ (WINTW).